Sodium-glucose cotransporter-2 (SGLT2) inhibitors, initially developed for diabetes, have revealed remarkable cardiovascular and renal protective properties, mitigating the risk of kidney replacement therapy and mortality, even in advanced CKD stages [6,77]. The gene discussed is SLC5A2; the disease is chronic kidney disease.